Public Sector Pension Investment Board Has $6.86 Million Position in Artivion, Inc. $AORT
Public Sector Pension Investment Board increased its stake in Artivion, Inc. (NYSE:AORT) by 23.7% in the third quarter, now owning 161,970 shares valued at approximately $6.86 million, representing 0.34% of the company. Other institutional investors also adjusted their positions, with overall institutional ownership at 86.37%. Artivion recently reported an EPS of $0.17, beating estimates, and revenue growth of 19.2% year-over-year to $118.3 million, while analysts maintain a "Moderate Buy" rating with a consensus target price of $48.97.
Artivion Earnings Call Highlights Growth, Margin Momentum
Artivion Inc. (AORT) reported robust Q4 and full-year 2025 results, demonstrating strong revenue growth, improved EBITDA margins, and significant deleveraging. While challenges like a cyber incident, tissue softness, and increased CapEx/R&D persist, management expressed confidence in achieving 2026 targets through growth in stent grafts and On-X valves, and ongoing clinical and regulatory advancements. The company projects continued double-digit revenue growth and margin expansion into 2026.
Artivion (NYSE:AORT) Stock Price Down 6.5% - Time to Sell?
Artivion (NYSE:AORT) shares dropped 6.5% during trading, falling below key moving averages, despite beating quarterly EPS and revenue expectations. Analysts maintain a "Moderate Buy" consensus, but insider selling and a negative net margin raise concerns. The article highlights these mixed signals and briefly describes Artivion as a global medical technology company specializing in implantable tissue products and surgical devices for cardiac and vascular surgery.
Artivion (AORT) Analyst Rating Update: Price Target Lowered by C
Canaccord Genuity has reaffirmed its "Buy" rating for Artivion (AORT) but has reduced the stock's price target to $48.00 from $51.00, a 5.88% decrease. Despite the lower target from Canaccord Genuity, the average one-year price target from 7 analysts is $51.71, suggesting a 46.21% upside from the current price. However, GuruFocus estimates a fair value of $26.42, indicating a potential downside of 25.3% for the stock.
Canaccord Genuity lowers Artivion stock price target to $48 on market compression
Canaccord Genuity has reduced its price target for Artivion Inc. (NYSE:AORT) to $48 from $51, while maintaining a Buy rating, due to compressed multiples in comparable groups amid a recent stock market sell-off. Despite this reduction, the new target still implies a 26% upside from the current trading price. Artivion reported strong fourth-quarter adjusted revenues and EBITDA, exceeding analyst estimates, and has a promising product pipeline expected to drive future growth, with analysts anticipating the company to become profitable this year.
Artivion, Inc. (NYSE:AORT) Q4 2025 Earnings Call Transcript
Artivion, Inc. reported its Q4 and full-year 2025 earnings, highlighting a strong performance with total adjusted constant currency revenue growth of 13% and adjusted EBITDA growth of 26% for the full year. Despite missing EPS expectations, the company saw significant growth in stent grafts (36%) and On-X revenues (24%), driven by market share gains and new clinical data. Artivion also provided an optimistic outlook for 2026, projecting 10-14% constant currency growth, while investing in R&D and capacity expansion for future product approvals and market penetration.
Artivion (AORT) Stock Trades Down, Here Is Why
Artivion (AORT) shares dropped 5.8% after reporting mixed fourth-quarter 2025 financial results, with revenues missing analyst expectations despite their non-GAAP profit being in line. Although the company provided a positive full-year revenue and EBITDA outlook for 2026, investors focused on the top-line miss. Artivion's stock is down 15.3% year-to-date and is trading 21% below its 52-week high.
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations
Artivion (NYSE:AORT) reported Q4 CY2025 revenue of $116 million, missing analyst estimates but showing a 19.2% year-on-year increase. The company's full-year revenue guidance exceeded expectations, and its non-GAAP EPS was in line with consensus. Despite the revenue miss and a slight dip in stock price post-announcement, Artivion showcased strong adjusted constant currency revenue growth for the full year 2025 and improved operating margins.
Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations
Artivion (NYSE:AORT) reported Q4 CY2025 revenue of $116 million, missing analyst expectations by 0.8% but still representing a 19.2% year-on-year growth. The company's full-year 2026 revenue guidance slightly exceeded estimates, and its adjusted EPS was in line with analyst consensus. Despite missing revenue targets, Artivion showed strong operating margin improvement and robust long-term EPS growth.
Earnings Flash (AORT) Artivion, Inc. Reports Q4 Revenue $116.0M, vs. FactSet Est of $116.5M
Artivion, Inc. (AORT) reported its Q4 revenue as $116.0 million, falling slightly short of FactSet's estimate of $116.5 million. The medical device company specializes in products for cardiac and vascular surgical procedures. This announcement was made on February 12, 2026, at 04:28 pm EST.
Artivion: Q4 Earnings Snapshot
Artivion, Inc. (AORT) reported a net income of $2.4 million for the fourth quarter, a turnaround from a loss in the previous year, with adjusted earnings of 17 cents per share. The biological medical device company achieved $116 million in revenue for the quarter and $441.3 million for the full year, swinging to a profit of $9.8 million. Artivion forecasts full-year revenue between $486 million and $504 million, despite its shares declining 11% year-to-date.
Artivion: Q4 Earnings Snapshot
Artivion, Inc. (AORT) reported a net income of $2.4 million in the fourth quarter, a significant improvement from a loss in the previous year, with adjusted earnings of 17 cents per share. The company posted quarterly revenue of $116 million and full-year revenue of $441.3 million, achieving a net income of $9.8 million for the year. Artivion anticipates full-year revenue for the upcoming period to be between $486 million and $504 million, while its shares have seen an 11% decline year-to-date, despite a 36% rise over the last 12 months.
Artivion: Q4 Earnings Snapshot
Artivion, Inc. (AORT) reported a net income of $2.4 million in the fourth quarter, a significant improvement from a loss in the same period last year. The medical device maker achieved 5 cents per share and a revenue of $116 million for the quarter. For the full year, Artivion posted a net income of $9.8 million on revenues of $441.3 million and projects future revenues between $486 million and $504 million.
Artivion: Q4 Earnings Snapshot
Artivion, Inc. (AORT) reported a net income of $2.4 million for the fourth quarter, or 5 cents per share, reversing a loss from the previous year. Adjusted earnings were 17 cents per share on revenues of $116 million. For the full year, the biological medical device maker achieved a net income of $9.8 million, or 21 cents per share, with total revenues of $441.3 million.
Artivion: Fourth Quarter Financial Highlights
Artivion, Inc. reported a net profit of $2.4 million for the fourth quarter, a significant improvement from a loss in the previous year, with adjusted earnings of $0.17 per share. The medical device manufacturer generated $116 million in revenue and projects annual revenue between $486 million and $504 million. Despite an 11% year-to-date decline, the company's stock has risen 36% over the past year, closing at $40.71.
Assessing Artivion (AORT) Valuation After Trial Successes And Upcoming Earnings Catalysts
Artivion (AORT) has released positive one and two-year clinical results from its NEXUS TRIOMPHE and AMDS PERSEVERE aortic repair trials, bringing fresh attention ahead of its upcoming earnings report. Despite recent short-term stock pressure, the company has shown strong long-term performance. While Artivion is considered 22% undervalued by Simply Wall St's narrative model, its current P/S ratio suggests the market has high expectations for future growth and margins.
What To Expect From Artivion's (AORT) Q4 Earnings
Artivion (AORT) is set to report its Q4 earnings this Thursday. Analysts project a 20.2% year-on-year revenue growth to $117 million and adjusted earnings of $0.18 per share. The company has a history of exceeding revenue estimates, and recent peer performance in the healthcare equipment sector offers mixed signals.
Artivion reports positive clinical data from aortic arch trials
Artivion Inc. announced positive clinical data from two trials (NEXUS TRIOMPHE IDE and AMDS PERSEVERE IDE) evaluating treatments for aortic arch disease, presented at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial showed 94% patient survival at one year with the NEXUS device, while the AMDS PERSEVERE trial demonstrated continued clinical benefits for acute DeBakey Type I aortic dissection. These results underscore the potential of Artivion's devices, with the company anticipating profitability this year and significant revenue growth, alongside recent strong Q3 2025 earnings and raised future guidance.
Assessing Artivion (AORT) Valuation After Positive NEXUS TRIOMPHE And AMDS PERSEVERE Trial Updates
Artivion (AORT) shares are under scrutiny following positive clinical data from its NEXUS TRIOMPHE and AMDS PERSEVERE trials. Despite recent share price declines, the company has shown strong long-term returns, and analysts project a fair value of $51.71, suggesting it is currently undervalued compared to its last close of $41.23, driven by the potential of its AMDS market penetration. However, the company's price-to-sales ratio is higher than industry averages, indicating potential valuation risk if growth or margins don't meet expectations.
Artivion reports positive clinical data from aortic arch trials By Investing.com
Artivion, Inc. announced positive clinical data from two trials evaluating treatments for aortic arch disease, presented at the Society of Thoracic Surgeons' 62nd Annual Meeting. The NEXUS TRIOMPHE IDE trial showed high patient survival and freedom from disabling stroke and reintervention, while the AMDS PERSEVERE IDE trial demonstrated continued clinical benefits with minimal mortality. Artivion is projected to become profitable this year, with strong revenue growth and analysts raising price targets due to recent positive earnings and future prospects.
Needham Reiterates Buy Rating for Artivion (AORT) with $58 Targe
Needham has reiterated its Buy rating for Artivion (AORT) and maintained a $58 price target, reflecting a consistent positive outlook from analysts. Over the past few months, multiple analysts have raised price targets and reaffirmed Buy or Market Outperform ratings for Artivion. While the average analyst target implies a 25.68% upside, GuruFocus' estimated GF Value suggests a 35.79% downside, indicating a divergence in valuation perspectives.
Artivion, Inc. Announces Presentation of Positive New Clinical Data from Endospan's Nexus Trial and its Amds PERSEVERE IDE Trial
Artivion, Inc. announced positive new clinical data from its Endospan's NEXUS TRIOMPHE IDE trial and AMDS PERSEVERE IDE trial, presented at the 62nd Annual Meeting of the Society of Thoracic Surgery. The NEXUS trial showed strong patient survival and freedom from disabling stroke at one year for high-risk patients, while the AMDS PERSEVERE trial demonstrated notable clinical and radiographic outcomes over two years for acute DeBakey Type I dissection. These trials evaluate devices designed for endovascular treatment of aortic conditions and hybrid prosthesis for open repair, respectively.
94% survival, 91% stroke-free in Artivion aortic trials
Artivion (NYSE: AORT) recently presented positive clinical data from its NEXUS TRIOMPHE and AMDS PERSEVERE IDE trials at the 62nd Society of Thoracic Surgeons Annual Meeting. The NEXUS TRIOMPHE trial reported a 94% patient survival rate from lesion-related death and 91% freedom from disabling stroke at one year. The AMDS PERSEVERE trial showed persistent positive aortic remodeling and zero distal anastomotic new entry tears through two years, with minimal additional morbidity.
Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting
Artivion, Inc. announced the presentation of positive new clinical data from its NEXUS TRIOMPHE and AMDS PERSEVERE IDE trials at the 62nd Annual Meeting of the Society of Thoracic Surgeons. The NEXUS TRIOMPHE trial showed high patient survival and low morbidity at 1-year for high-risk patients with aortic arch disease, while the AMDS PERSEVERE trial demonstrated continued positive aortic remodeling and minimal morbidity at 2-years for acute DeBakey Type I aortic dissection patients. These results further validate these therapeutic options for complex aortic conditions.
Is Artivion (AORT) Pricing Look Risky After Strong 1-Year Share Price Run?
Artivion (AORT) has seen significant share price appreciation over the past year, but a recent analysis by Simply Wall St suggests it may be overvalued. Both a Discounted Cash Flow (DCF) analysis and a Price-to-Sales (P/S) ratio comparison indicate the stock is trading above its fair value. The article encourages investors to consider different valuation narratives and provides tools for further research.
Artivion (NYSE:AORT) Downgraded to Buy Rating by Wall Street Zen
Wall Street Zen has downgraded Artivion (NYSE:AORT) from a "strong-buy" to a "buy" rating, though the stock maintains a "Moderate Buy" consensus among analysts with an average target price of $49.11. Despite beating Q3 earnings estimates, the company remains unprofitable with a negative net margin. Insider sales totaling over $10.6 million have reduced insider ownership to 7.6%, while institutional investors hold approximately 86.4% of the shares.
Are Options Traders Betting on a Big Move in Artivion Stock?
This article analyzes unusual options activity for Artivion (AORT), indicating that a significant portion of options traders are predicting a large move in the stock. It highlights a bullish sentiment based on a large put option sweep and discusses the concept of option "sweeps" as indicators of institutional investor interest. The piece also provides financial details for Artivion, including its current stock price and upcoming earnings report.
Even though Artivion (NYSE:AORT) has lost US$81m market cap in last 7 days, shareholders are still up 236% over 3 years
Artivion, Inc. (NYSE: AORT) shareholders have seen a 236% return over the last three years, despite a recent US$81 million market cap loss. The company, which is currently unprofitable, has demonstrated a respectable 10% annual revenue growth over the same period, leading to a 50% per year share price increase. Its one-year total shareholder return stands at 46%, indicating improved performance recently.
Even though Artivion (NYSE:AORT) has lost US$81m market cap in last 7 days, shareholders are still up 236% over 3 years
Artivion (NYSE:AORT) shareholders have seen a significant 236% return over the past three years, despite a recent US$81 million market cap loss. The company, which is currently unprofitable, has demonstrated a respectable annual revenue growth of 10% over the last three years. This strong revenue growth likely contributes to the positive long-term share price performance.
Artivion, Inc. (NYSE:AORT) Receives Average Rating of "Moderate Buy" from Analysts
Artivion, Inc. (NYSE:AORT) has received a "Moderate Buy" consensus rating from nine brokerages, with an average one-year price target of $49.11. Despite beating last quarter's earnings and revenue estimates, the company reported a negative net margin and P/E ratio, indicating ongoing unprofitability. Insider selling has also been significant, with executives liquidating shares worth over $10 million in the past 90 days.
Artivion Insiders Sold US$9.8m Of Shares Suggesting Hesitancy
Artivion Inc. (NYSE:AORT) insiders have sold a substantial US$9.8 million worth of shares over the last year, with US$5.5 million sold in the last three months alone, suggesting hesitancy about the company's valuation. Despite this, insiders still hold 4.6% of the company, valued at approximately US$97 million. The significant insider selling, particularly by Chairman James Mackin, indicates that insiders may not view the stock as cheap, urging investors to consider this trend carefully.
3 Reasons to Sell AORT and 1 Stock to Buy Instead
This article argues for selling Artivion (AORT) despite its recent stock increase, citing three main concerns: limited distribution channels due to small scale, breakeven free cash flow hindering reinvestment, and mediocre performance of previous growth initiatives. The author suggests looking for better opportunities elsewhere, specifically recommending a well-established endpoint security platform or other high-quality momentum stocks.
Squarepoint Ops LLC Takes $664,000 Position in Artivion, Inc. $AORT
Squarepoint Ops LLC initiated a new position in Artivion (NYSE:AORT) in Q2, acquiring 21,362 shares valued at approximately $664,000. Institutional investors now collectively own about 86.37% of the company, and analysts have a bullish outlook with an average target price of $49.11. Despite positive Q3 earnings beats and revenue growth, recent insider selling has been significant, totaling over $10 million in the past three months.
Wall Street Zen Upgrades Artivion (NYSE:AORT) to Strong-Buy
Wall Street Zen has upgraded Artivion (NYSE:AORT) from "buy" to "strong-buy," with other analysts also raising price targets, leading to a consensus "Moderate Buy" rating with a $49.11 target. The company surpassed quarterly earnings expectations, reporting $0.16 EPS against $0.14 expected and revenues of $113.39 million, an 18.9% increase year-over-year. Despite recent insider selling, institutional ownership remains high at approximately 86.4%, while the stock trades near its 52-week high.
Assessing Artivion (AORT) Valuation After Analyst Upgrades and New On-X Valve Clinical Data
Artivion (AORT) stock has seen a significant climb following positive analyst commentary and new clinical data for its On-X mechanical heart valve, suggesting expanded market potential. While a narrative valuation indicates the stock is 10% undervalued at $51.71, a price-to-sales analysis suggests it is expensive compared to the US medical equipment sector. Investors are encouraged to conduct their own research to determine if the growth prospects justify the current valuation.
Artivion Inc stock hits all-time high at 48.06 USD
Artivion Inc. (AORT) stock reached an all-time high of $48.06, reflecting a significant milestone with a 58.86% one-year return and strong investor confidence. The company reported impressive Q3 2025 earnings, surpassing analyst expectations with an EPS of $0.16 and revenues of $113.4 million, leading to raised revenue and EBITDA guidance. Several analysts, including Oppenheimer, Needham, and Canaccord Genuity, have increased their price targets and maintained positive ratings, citing the company's strong performance and future product pipeline.
Why Artivion (AORT) Is Up 6.7% After New On-X Valve Studies Bolster Analyst Confidence
Artivion (AORT) saw its stock rise by 6.7% following a reaffirmed positive rating from Canaccord Genuity, driven by new clinical studies supporting its On-X mechanical heart valves for younger patients. This clinical backing and analyst confidence are expected to influence demand and reinforce Artivion's growth prospects, although its ongoing success depends on continued innovation and new product launches to complement existing offerings. The company recently raised its 2025 revenue and EBITDA guidance, indicating strong performance but also setting a higher bar for future execution.
Artivion Inc stock hits all-time high at 48.06 USD By Investing.com
Artivion Inc. stock reached an all-time high of $48.06, reflecting strong investor confidence and impressive performance with significant gains over the past year. The company recently reported strong third-quarter 2025 earnings, surpassing forecasts and leading analysts to raise price targets and reiterate positive ratings. Future growth is also anticipated from its aortic stent graft portfolio, including NEXUS and Arcevo products awaiting FDA approvals.
Why Artivion (AORT) Is Up 6.7% After New On-X Valve Studies Bolster Analyst Confidence
Artivion's stock rose 6.7% due to new clinical studies supporting its On-X mechanical heart valves for younger patients, reinforcing analyst confidence from Canaccord Genuity. This clinical backing and reaffirmed ratings enhance Artivion's growth narrative, particularly as the company focuses on translating strong clinical data into increasing procedure volumes and improved profitability. However, future performance hinges on continued innovation and successful new product launches beyond its established products.
Artivion, Inc. (NYSE:AORT) Given Consensus Rating of "Moderate Buy" by Analysts
Artivion, Inc. (NYSE:AORT) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month target price of $49.11. Despite significant insider selling totaling over $10.6 million in the last three months, institutional investors have increased their stakes. The company topped Q3 earnings and revenue estimates, though it still faces a negative net margin and PE ratio.
Insider Sell: John Davis Sells 5,000 Shares of Artivion Inc (AOR
John Davis, Chief Commercial Officer at Artivion Inc, sold 5,000 shares of the company on December 15, 2025. This transaction leaves him with 193,842 shares. Artivion Inc's stock is currently trading at $45.11, significantly overvalued compared to its GuruFocus Value of $23.54.
Artivion (AORT) Stock Is Up, What You Need To Know
Artivion (AORT) shares jumped 4.6% after Canaccord Genuity reaffirmed its Buy rating and $51.00 price target, citing growth potential in its On-X mechanical valve business and new clinical studies. Other analysts also raised price targets, reflecting increased confidence. The stock is up 67.4% year-to-date and trading near its 52-week high, with the market perceiving recent positive news as meaningful for the company.
Artivion Inc stock hits all-time high at 48.06 USD By Investing.com
Artivion Inc.'s stock (AORT) reached an all-time high of $48.06, driven by strong investor confidence and impressive financial performance, including a 58.86% one-year return and a recent beat on Q3 2025 earnings. Analysts maintain optimistic outlooks with raised price targets, reflecting confidence in the company's future prospects and upcoming product launches.
Canaccord Genuity reaffirms Buy rating on Artivion stock at $51 target
Canaccord Genuity has reiterated its Buy rating on Artivion Inc. (NYSE:AORT) with a $51.00 price target, following positive discussions with company leadership regarding commercial roll-out strategies and future product pipelines. Analysts anticipate significant upside opportunities, with Artivion expected to achieve profitability this year and projected to see 14% revenue growth for fiscal year 2025, supported by new FDA approvals and market expansion efforts. The optimistic outlook is also shared by other analysts, who have similarly raised price targets for the stock based on strong third-quarter earnings.
Artivion Inc stock hits all-time high at 48.06 USD By Investing.com
Artivion Inc. (AORT) stock has climbed to an all-time high of $48.06, reflecting strong investor confidence with a 58.86% one-year return. The company recently reported impressive Q3 2025 earnings, significantly surpassing analyst expectations for both EPS and revenue, leading several analysts to raise their price targets and reiterate "Buy" or "Outperform" ratings. Analysts remain optimistic about Artivion's future, particularly its upcoming aortic stent graft products.
Canaccord Genuity reaffirms Buy rating on Artivion stock at $51 target
Canaccord Genuity reiterated its Buy rating and $51.00 price target for Artivion Inc. following a non-deal roadshow with the company's CEO and CFO. The discussions highlighted future growth initiatives, including the AMDS US commercial roll-out and upcoming aortic stent graft products like NEXUS and Arcevo, alongside the reacceleration of the On-X mechanical valve business. Analysts anticipate Artivion becoming profitable this year with a forecasted EPS of $0.63, underpinned by strong recent earnings and raised guidance.
Artivion (AORT) Stock Is Up, What You Need To Know
Artivion (AORT) shares rose 4.6% after Canaccord Genuity reaffirmed its Buy rating and $51 price target, citing growth potential from their On-X mechanical valve business and two new clinical studies. Oppenheimer and Needham also raised their price targets to $50 and $58, respectively, maintaining positive ratings. The stock, which is up 67.4% year-to-date and near its 52-week high, has seen a 2.4% increase since the previous close despite cooling from its initial pop.
We Think Artivion (NYSE:AORT) Is Taking Some Risk With Its Debt
Artivion, Inc. (NYSE:AORT) carries significant debt, totaling US$214.9m as of September 2025, leaving a net debt of US$141.4m after accounting for cash. The company's interest coverage is weak at 0.86, and its EBIT has dropped by 10% in the last year, suggesting potential risks despite a US$2.14b market capitalization. Free cash flow conversion from EBIT is also low at 7.1%, raising concerns about its ability to manage its debt load.
Does Artivion’s 2025 Surge Still Make Sense After Recent Medtech Rally?
Artivion has experienced significant stock growth but scores 0/6 on valuation checks and appears overvalued according to Discounted Cash Flow and Price to Sales analyses. The article delves into these valuation methods, suggesting that despite market enthusiasm for medtech, Artivion's current price may not be supported by its underlying financial projections. It also introduces the "Narratives" framework from Simply Wall St for a more personalized valuation approach.
Artivion (NYSE:AORT) Cut to "Buy" at Wall Street Zen
Wall Street Zen downgraded Artivion (NYSE:AORT) from "strong-buy" to "buy" despite most other brokers maintaining positive ratings with a consensus "Moderate Buy" and an average price target of $49.11. The company exceeded last quarter's earnings and revenue estimates, though it reported a negative net margin. Insider selling occurred recently, even as institutional ownership remains high and large funds have increased their positions.
